Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia,

myelofibrosis. In conclusion, our observations from the current study do not support the consideration of ExT as a risk factor for thrombosis, in otherwise low-risk ET, and question the value of prophylactic cytoreductive therapy in the particular scenario; a similar observation was recently communicated regarding the use of hydroxyurea in ET patients age 40–59 years and without risk factors for thrombosis or platelet count ≥1500 × 10/L; a prospective controlled study is needed for further clarification and confirmation of the observed benefit from aspirin therapy in the current retrospective study.